Vabysmo™ (faricimab-svoa intravitreal)

Vabysmo (faricimab‑svoa intravitreal) is covered only for the FDA‑approved indications—neovascular (wet) AMD, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO)—and is not covered for non‑FDA‑approved uses. Coverage requires administration by or under the supervision of an ophthalmologist, dosing of 6 mg intravitreal no more frequently than every 4 weeks, documentation of diagnosis and dosing, and authorization is granted for up to 12 months.

"Neovascular (wet) age-related macular degeneration (nAMD)"

Sign up to see full coverage criteria, indications, and limitations.